| INTRODUC TI ON
The availability of direct-acting antivirals (DAAs) has revolutionized the management of HCV infection in liver transplantation (LT) candidates and recipients. [1] [2] [3] [4] [5] Nowadays, these once "difficult-to-treat patients" can be safely treated with interferon-free regimens with very high success rates. Several strategies for HCV treatment have been proposed, including the following: (i) treatment prior to LT to prevent HCV infection of the graft and to possibly delist some patients due to clinical improvement, 1, 4 (ii) perioperative treatment starting as soon as a liver becomes available; in this respect, a recent phase 2 trial reported a sustained virologic response (SVR) of 88% in patients treated for only 4 weeks 3 and (iii) treatment of recurrent disease. 5 After almost 3 years of prescribing DAAs, the best timing for treating LT candidates is still unclear. 2, [5] [6] [7] The aim of this study was to compare the cost-effectiveness of the aforementioned three strategies in patients with decompensated cirrhosis (DCC) or with hepatocellular carcinoma (HCC) listed for LT.
| MATERIAL S AND ME THODS

| Overview
Based on a previously published model, 6 we developed a decision analytical Markov model to simulate the progression of a HCV-infected cirrhotic with or without HCC from the time of listing until death, and we used this model to study the cost-effectiveness of the three strategies proposed. The parameters were estimated to reflect two specific subgroups of HCV-positive LT candidates: patients listed for DCC and patients with a transplantable HCC. This distinction was made to account for the probability of DCC patients to be delisted due to clinical improvement after DAAs treatment. 4 The DCC subgroup was further divided into three categories based on MELD score (MELD<16, MELD [16] [17] [18] [19] [20] to reflect the different probability to be delisted according to the MELD score at start of therapy. 4 For each treatment strategy, the model estimated the costs, the life years (LYSs), the quality-adjusted life years (QALYs) and the in- 
| Treatment strategies
Three treatment strategies were modelled:
1. 12-week DAAs course when patients are listed for LT (PRE-LT).
4-week DAAs course started the day of LT (PERI-LT),
3. 12-week DAAs course at the time of significant disease recurrence defined as METAVIR fibrosis F3 (POST-LT). 
| Input parameters for the model
In patients with DCC, simulations were based on the population enrolled in the ELITA study. 4 The probabilities of receiving a LT, of being delisted, of dropping out because of clinical worsening (futile transplantation) and of dying were derived from the original data set of 103 patients with decompensated cirrhosis without HCC treated with DAAs that were reported in the ELITA study. 4 The ELITA data set was updated in September 2016 and now includes 39 new patients. One hundred and forty-two patients included in the more recent data set were stratified into three MELD categories (MELD<16, MELD [16] [17] [18] [19] [20] and MELD>20) as reported in the previous study to differentiate the probability of being inactivated/delisted. The incidences of delisting, receiving a LT, dying or dropping out while on the WL were stratified for each MELD subgroup ( Figure 2) and used in the present model to estimate the transition probability of treated DCC in the WL. Finally, an extensive literature review was performed to obtain the reference data upon which to set the values of the other parameters to be used in the model. When specific data were not available, some assumptions were made based on the opinion of experts. Table 1 reports a summary of transition probability of the parameters used in the base case analysis for 4 cohorts used in the model. Table S1 reports the value of utility weights associated with each health status used to estimate QALYs and the cost associated with treatment and to each health states. In the Data S1, additional information regarding methods and assumptions used to estimate the values of the parameters is available.
| Analysis
The as the difference in the expected cost produced by the two interventions divided by the difference in the expected QALYs produced by the two interventions) using the most effective treatment as a reference. To be considered cost-effective, the ICER should be under the willingness to pay (WTP) threshold of 40,000 € per QALY gained, which is considered acceptable by leading regulatory agencies such as NICE-UK, AHRQ-USA and CADTH-Canada. 6 The SVR probability of PERI-LT was derived from a phase 2 clinical trial with only 16 patients, 3 due to the small sample size, the possible different efficacies of PERI-LT (88%) with POST-LT (96%)
could be related to chance. Based on this uncertainty, an alternative scenario with a SVR probability of 96% for both POST-LT and
PERI-LT strategies was tested, assuming 6-week treatment duration for PERI-LT strategy. Different DAAs treatment costs were also tested, higher (€25 000 per 12 weeks = €2083 per week) and lower (€10 000 per 12 weeks = €833 per week) DAAs costs were assessed to estimate the impact of DAAs treatment cost on the costeffectiveness results. 11 Further, we assessed the impact of changing delisting probability associated with DAAs treatment in the DCC patients. The delisting probability uncertainty was based on the data in the updated data set by the ELITA study. 4 Finally, the robustness of the model's assumption and the impact of the other parameters on the results were tested performing a one-way sensitivity analysis by changing parameters using a plausible range or the 95% confidence interval (Table 1) .
A probabilistic sensitivity analysis was performed to address the uncertainty of the model parameters. Statistical distributions were assigned to the model parameters to evaluate the uncertainty around the point estimates. Uncertainty of all model parameters was assessed using a Monte Carlo simulation, drawing parameter values at random 1000 times from the appropriate corresponding distributions. The results from the simulations were used to generate cost-effectiveness acceptability curve (CEAC) in order to explore the probability of each treatment strategies to be economically attractive. The CEAC indicate the probability that each treatment is cost-effective, given the values and uncertainty of the parameters used in the model and for different values of the acceptable WTP.
The validation of the model was based on the predicted survival rate of patients with DCC and HCC according to the data available in the literature (Data S2).
| RE SULTS
Results shown in Table 2 
TA B L E 1 (Continued)
MELD 16-20, the PRE-LT strategy remained dominant compared to the POST-LT strategy, while more effective but also more costly when compared to the PERI-LT strategy with an ICER of €7,563
per QALY gained.
In DCC patients listed with a MELD>20 and in those with HCC, the POST-LT approach emerged as the best option (Table 2 ). In the case of DCC with MELD>20, the POST-LT strategy was more effective but also more costly with an ICER of €836 and €24 840 per QALY gained compared to PRE-LT and PERI-LT options. In patients with HCC, the POST-LT strategy was dominant compared to PRE-LT, while it showed an ICER of €28 698 per QALY compared to PERI-LT.
| Sensitivity analysis
Sensitivity analyses on three different scenarios were performed to estimate the effects of different SVR probability after PERI-LT strategy, different DAAs costs and different delisting probabilities on ICERs.
Scenario 1, we assumed that the PERI-LT and the POST-LT strategies had the same 96% probability of achieving an SVR. Even under these conditions, DAA given PRE-LT remained the best option for DCC patients with MELD<16 and MELD 16-20, while for those with MELD>20 or with HCC, the PERI-LT strategy emerged as dominant due to a lower overall cost and similar efficacy (Table 3) .
Scenario 2, we tested the impact of cost of DAA. When we assumed a lower DAAs weekly cost (€803 instead of €1250), no significant effect on cost-effectiveness was observed; on the other hand, a higher DAAs weekly cost (€2083 instead of €1250) had a significant impact on the ICER estimated for patients with HCC where the PERI-LT strategy became the most cost-effective ( Figure 3) .
Scenario 3, we tested two different delisting probability for the 2 subgroups of patients with MELD<16 and 16-20. In both situations, the PRE-LT strategy was dominant in the MELD<16 group, while the POST-LT strategy was the most cost-effective compared to the other two options when a lower probability of delisting (almost 4.0% in 1.5 years) was assumed in the MELD 16-20 group. Lower delisting probability reduced the advantages of PRE-LT treatment in terms of chances of avoiding a LT (Table S2) .
The other model parameters tested in the sensitivity analysis are reported in the Data S3. These analyses showed that ICERs were more sensitive to changes in mortality of HCV patients with mild or moderate fibrosis after transplant, LT probability in treated and not treated patients, LT mortality in treated and untreated patients and mortality rate in patients delisted for clinical improvement due to
DAAs treatment.
The WTP threshold is not a fixed parameter, but varies according to several socio-economic conditions and the policy of each specific healthcare system. 7 Thus, the results of the probabilistic sensitivity analysis were used to generate a cost-effectiveness acceptability curves (CEACs) in order to assess the probability of each treatment strategy to be economically attractive at different cost-effectiveness threshold ( Figure 4) . Assuming a WTP of €40 000, CEACs showed that, for patients with DCC and MELD<16, there was a 99% probability that the PRE-LT strategy was cost-effective ( Figure 4A) . Similarly, the PRE-LT strategy resulted in a much lower 60% probability to be cost-effective in the case of patients with DCC and MELD [16] [17] [18] [19] [20] ( Figure 4B ). Whereas, in the case of patients with DCC MELD>20
and in the case of those with HCC, the POST-LT strategy had the highest probability to be cost-effective ( Figure 4C-D) .
| D ISCUSS I ON
The results of this cost-effectiveness analysis demonstrate that "HCV treatment PRE-LT" is the most cost-effective strategy for For each subgroup of patients, the most effective strategies (higher discounted QALYs gained) were reported in the first row followed by the second and third effective strategies. HCC, hepatocellular carcinoma; ICER, incremental cost-effectiveness ratio; LYs, life years; QALYs, quality-adjusted life years.
a For each subgroup of patients, the most effective strategy was compared to each of the other two options to estimate the increment in costs, effects and to assess the relative ICER. Positive incremental LYs, QALYs and costs mean higher effectiveness and costs of treatment strategy reported in the first row, while negative costs values mean lower costs of treatment strategy reported in the first row.
b Dominant = the reference treatment is more effective and less costly than the alternative treatment strategy.
F I G U R E 3
Alternative scenario with lower and higher DAAs treatment cost. For each subgroup, the mean overall cost per patient was reported for each treatment strategy to show the impact in terms of cost of using a different DAAs price. For each scenario was indicated which treatment strategy resulted as the cost-effective option (ICER < €40 000 per QALY gained) For each subgroup of patients, the most effective strategies (higher discounted QALYs gained) were reported in the first row followed by the second and third effective strategies. HCC, hepatocellular carcinoma; ICER, incremental cost-effectiveness ratio; LYs, life years; QALYs, quality-adjusted life years. a For each subgroup of patients, the most effective strategy was compared to each of the other two options to estimate the increment in costs, effects and to assess the relative ICER. Positive incremental LYs, QALYs and costs mean higher effectiveness and costs of treatment strategy reported in the first row, while negative costs values mean lower costs of treatment strategy reported in the first row. b Dominant = the reference treatment is more effective and less costly than the alternative treatment strategy.
TA B L E 3 Alternative scenario with PERI-LT duration of 6 wk and SVR equal to POST-LT (96%)
patients with DCC and a MELD score equal or lower than 20. On the other hand, "treating patients POST-LT at the time of disease recurrence" emerged as the most cost-effective option for patients with DCC and a MELD score higher than 20 and for patients with HCC.
A number of sensitivity analyses were performed to test our results, with particular attention to three of the most relevant variables, namely expected rate of SVR after PERI-LT treatment, cost of DAA treatments and probability of delisting. In the case of patients with DCC and a MELD<16, PRE-LT treatment remained costeffective across all the simulations considered in the sensitivity analysis. Similar results were observed in the case of DCC patients with MELD 16-20, except when a low delisting probability was assumed. The possibility of delisting some DCC patients due to clinical improvement explains why PRE-LT treatment has such a major impact on cost saving as delisting eliminates or delays the need for LT. On the other hand, in the case of patients with HCC or with a MELD>20, the chances of being delisted due to clinical improvement are virtually nil. 4 In such patients, treating patients POST-LT is the most cost-effective strategy except when higher DAAs weekly cost (€2083 instead of €1250) was assumed. In this scenario, PERI-LT showed the possibility to be the cost-effective options in patients with HCC.
To the best of our knowledge, this is the first cost-effectiveness analysis that includes the effect of DAAs treatment on delisting probability using data from real clinical practice. 4 Furthermore, this is the first study that considers the option of a very short course of DAA started as soon as a liver becomes available. 3 Finally, it is one of the very few studies that consider HCC and DCC in the same model, 12, 13 as in most transplant centres, these patients compete for the same organs and resources.
Other studies have investigated the optimal timing of DAA treatment for patients listed for transplant, using a decision analytical model. 9, [12] [13] [14] The first was the study by Njei model and showed that antiviral therapy given PRE-LT was more cost-effective than if given post-LT. In all these studies, the positive effect of treating with DAA prior to LT was ascribed to a reduction in the MELD score and to a consequent lower risk of death while waiting for a LT. However, the impact of MELD reduction on survival could only be based on assumption because no real data were available at the time of their analyses. Further, none of the aforementioned studies included the true "risk" of delisting nor the option of treating patients with a very short course of DAA, as we did.
Some aspects of our study need to be discussed. Firstly, it is important to underline that long-term outcome data after delisting
are not yet available and once patients are delisted, a sizable risk of decompensation and of developing HCC remains, albeit strongly reduced. In the past, almost one-third of HBV patients were eventually delisted while on NUC therapy and the results of their clinical improvement could be maintained for up to 5 years. 15 Whether this favourable long-term outcome also holds true for HCV patients needs to be verified. Our study has some limitations that need to be addressed. Firstly, there is lack of data describing the natural history of patients with DCC or HCC post-SVR. As these patients are followed in the realworld, this analysis should be updated to reflect patient natural history with greater precision. Secondly, as long-term data on transplant recipients that achieve SVR are very limited, we assumed that patient survival would be similar to that of HBV recipients after curing their infection. This assumption is confirmed by the similar 5-year survival rate reported by the European Liver Transplant Registry for HBV patients 16 and by the North Italy Transplant programme for HCVnegative patients after LT, 17 79% and 83%, respectively. Thirdly, we assumed that patients would be treated only once and that would not have the option of retransplantation. Fourthly, we did not specifically factor in genotype 3 in the analysis, which may be a limit in areas where type 3 is highly prevalent. However, recent DAAs combinations resulted very effective across all genotypes, including type 3, reducing the issue associated with the different genotypes treatment. Fifthly, HCC-MELD exception points were not considered in our study. However, whatever the priority of a patient listed for HCC, postponing DAA therapy after LT emerged as the most cost-effective option because delisting was not possible in these patients. Sixthly, and last, no different DAAs combinations were assessed. However, due to the high and similar efficacy of the different DAAs combination available, we do not think that a cost-effectiveness analysis is required because they can be considered equal in terms of efficacy.
In our study, we have shown which treatment strategy based on a generic DAAs combination is most cost-effective in the different subgroup of patients, while the choice of which DAAs combination used should depend only on DAAs cost: the cheaper the better.
In conclusion, our study supports the cost-effectiveness of DAA 
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